Arcus Biosciences Inc (RCUS) has seen a significant price increase of 6.47%, reaching a 52-week high. This surge comes as the broader market, including the Nasdaq-100 and S&P 500, also experienced gains of 1.01% and 0.85%, respectively.
The recent performance of Arcus is indicative of strong investor sentiment in the biotech sector, particularly as the company continues to develop advanced cancer therapies. The positive market environment has likely contributed to this upward momentum.
In related news, while some stocks in the tech sector faced declines, Arcus Biosciences has managed to stand out, reflecting its unique position and potential in the market.
RCUS
$21.91+Infinity%1D
Analyst Views on RCUS
Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 28.38 USD with a low forecast of 14.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast RCUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCUS is 28.38 USD with a low forecast of 14.00 USD and a high forecast of 56.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 21.530
Low
14.00
Averages
28.38
High
56.00
Current: 21.530
Low
14.00
Averages
28.38
High
56.00
H.C. Wainwright
Buy
maintain
$28 -> $32
2025-12-12
New
Reason
H.C. Wainwright
Price Target
$28 -> $32
2025-12-12
New
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Arcus Biosciences to $32 from $28 and keeps a Buy rating on the shares. The firm updated its model to remove domvanalimab revenues in non-small cell lung cancer and gastrointestinal cancers as it now believes the odds of success for these are 0%, but it simultaneously increased its revenue estimates for casdatifan in second-line clear cell renal cell carcinoma based on highly positive monotherapy data, the analyst tells investors.
Truist
Buy
downgrade
$39 -> $30
2025-12-12
New
Reason
Truist
Price Target
$39 -> $30
2025-12-12
New
downgrade
Buy
Reason
Truist lowered the firm's price target on Arcus Biosciences to $30 from $39 and keeps a Buy rating on the shares. Arcus ended the Phase 3 STAR-221 trial after a futile analysis, eliminating domvanalimab+zmberelimab as a near-term catalyst and heightening pessimism around the broader TIGIT program, including Dom in non-small cell lung cancer, the analyst tells investors in a research note. Large R&D cuts are expected as the company pivots toward casdatifan, which remains a potential multi-billion-dollar opportunity backed by about $1B in cash and multiple 2026 catalysts.
Citi
Yigal Nochomovitz
Buy
downgrade
$56 -> $44
2025-12-12
New
Reason
Citi
Yigal Nochomovitz
Price Target
$56 -> $44
2025-12-12
New
downgrade
Buy
Reason
Citi analyst Yigal Nochomovitz lowered the firm's price target on Arcus Biosciences to $44 from $56 and keeps a Buy rating on the shares after the company announced that the Phase 3 STAR-221 trial has been discontinued due to futility observed at a pre-specified interim analysis. Following the news, the firm has removed domvanalimab plus zimberelimab in gastric-related indications from its valuation, but remains positive on casdatifan ahead of readouts in 2026, the analyst tells investors.
BofA
Neutral
maintain
$17 -> $26
2025-11-28
Reason
BofA
Price Target
$17 -> $26
2025-11-28
maintain
Neutral
Reason
BofA raised the firm's price target on Arcus Biosciences to $26 from $17 and keeps a Neutral rating on the shares after incorporating Taiho's option of RCC candidate casdatifan in its Arcus model while making "limited adjustments" to its forecasts following the company's Q3 earnings update.
About RCUS
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
